Quinethazone

Summary

Quinethazone (CHEMBL1532) is an approved small-molecule antihypertensive agent (ATC C03BA02); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C03BA02
• Indications: 1 condition
• Chemistry: 289.74 Da · C10H12ClN3O3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1532
Name	Quinethazone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6307
ChEBI	CHEBI:8717
ATC	C03BA02
Molecular formula	C10H12ClN3O3S
Molecular weight	289.74
InChIKey	AGMMTXLNIQSRCG-UHFFFAOYSA-N

SMILES: CCC1NC2=CC(=C(C=C2C(=O)N1)S(=O)(=O)N)Cl

IUPAC name: 7-chloro-2-ethyl-4-oxo-2,3-dihydro-1H-quinazoline-6-sulfonamide

ChEBI definition: A member of the class of quinazolines that is quinazolin-4-one substituted at positions 2, 6 and 7 by ethyl, sulfamoyl and chloro groups respectively; a thiazide-like diuretic used to treat hypertension.

Pharmacological roles (ChEBI): antihypertensive agent, diuretic.

Also known as: Hydromox, NSC-759904, Quinetazona, Quinethazone, Quinethazone component of hydromox r, QUINETHAZONE, SID56463176, SID144203917, SID170465167, quinethazone

Patent coverage: 1,477 distinct patent families (5,556 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,543 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).